Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026

HomeCompaniesSectorsCalendarLast night
Screens
WarningsPrice and conditionThen and nowSize bandsCeased filers
Tools
Time machinePoint in timeData exportsRun logForecast logEDGAR company search
Method
MethodCoverageAbout
Phio Pharmaceuticals Corp.PHIO · healthcare
GradeNonecomputable_factors_below_threshold: 3 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $21.5M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, thin data, degenerate inputsnot computable: distress, fortress balance sheet
Inputs computable3 of 14
Graded fromfilings received through Mar 5, 2026218 days before the rescan; every figure keyed to the SEC receipt date
Last close$0.982026-10-08; market equity $11.4M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$1$2NovDecJanFebMarAprMayJunJulAugSepOct$0.97
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Apr 21, 2013nonen/aQ1
Apr 21, 2014nonen/aQ2
Apr 21, 2015nonen/aQ1
Apr 21, 2017nonen/aQ2
Apr 21, 2018nonen/aQ1
Apr 21, 2019nonen/aQ2
Apr 21, 2020nonen/aQ1
Apr 21, 2021nonen/aQ2
Apr 21, 2024nonen/aQ1
Mar 21, 2026nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 5, 2026; the document on sec.gov.

Phio Pharmaceuticals Corp. (“Phio,” “we,” “our” or the “Company”) is a clinical stage biopharmaceutical company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 143.1%[3-4]
Thin data. 3 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 60.7
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(5.3%)[1,5-7](6.6%)60.78112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency
Twelve-month failure probabilitynot computable0.07%
latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-primenot computable(0.31)
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current rationot computable2.96x
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Growth and financing, sleeve percentile 54.6
Revenue growth, three-year compoundnot computable10.0%
current value must be positive and the base must exceed $100,000
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years18.8%[1,7-9]2.1%22.07042025-12-31
Net share issuance, one year143.1%[3-4]2.5%87.26342026-03-02

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(56.0%)8.0%11hotter than 11 of 100 peers
Distance from 52-week high(59.8%)(31.4%)18closer to its high than 18 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(70.7%)(1.0%)8pricier than 92 of 100 peers
Book value to price1.110.2889pricier than 11 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five years453.0%20.3%97more equity-funded than 97 of 100 peers
Relative strength against the sector, log excess return(1.03)(0.14)11ahead of 11 of 100 peers

Inputs: market equity $11.3M; EBIT -$9.2M; free cash flow -$8.0M; book equity $12.6M; sales $0; cash $13.0M[10].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(151.6%)✗ fail[5,7]
Operating cash flow above zero-$8.0M✗ fail[6]
Return on assets improved(75.2 pts)✗ fail[5,7-8,11]
Operating cash flow exceeds net income$719,000✓ pass[5-6]
Long-term leverage felln/a[1,7-8]
Current ratio improvedn/a[12-14]
No new shares issued143.1%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improvedn/a[7-8]
Cash, filings, liquidity
Cash and equivalents$13.0M[15]
Operating cash flow, four quarters-$12.2M[6,15-19]
Months of runway12.8
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing64
10-Q received Aug 6, 2026
Median daily dollar volume$110,546
63 sessions
Days since newest grade input218

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$21.5M2025-12-312026-03-0510-Kfiling · viewer · series
2revenueus-gaap:Revenues$02020-12-312021-03-2510-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding11,617,2502026-03-022026-03-0510-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding4,778,1542025-03-202025-03-3110-Kfiling · viewer · series
5net incomeus-gaap:NetIncomeLoss-$8.7M2025-12-312026-03-0510-Kfiling · viewer · series
6operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.0M2025-12-312026-03-0510-Kfiling · viewer · series
7assetsus-gaap:Assets$5.7M2024-12-312026-03-0510-Kfiling · viewer · series
8assetsus-gaap:Assets$9.4M2023-12-312025-03-3110-Kfiling · viewer · series
9assetsus-gaap:Assets$12.8M2022-12-312024-04-0110-Kfiling · viewer · series
10shares outstandingdei:EntityCommonStockSharesOutstanding11,617,2502026-08-042026-08-0610-Qfiling · viewer · series
11net incomeus-gaap:NetIncomeLoss-$7.2M2024-12-312026-03-0510-Kfiling · viewer · series
12current assetsus-gaap:AssetsCurrent$21.5M2025-12-312026-03-0510-Kfiling · viewer · series
13current assetsus-gaap:AssetsCurrent$5.7M2024-12-312026-03-0510-Kfiling · viewer · series
14current liabilitiesus-gaap:LiabilitiesCurrent$1.0M2024-12-312025-03-3110-Kfiling · viewer · series
15cashus-gaap:CashAndCashEquivalentsAtCarryingValue$13.0M2026-06-302026-08-0610-Qfiling · viewer · series
16operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.0M2026-06-302026-08-0610-Qfiling · viewer · series
17operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$4.0M2026-03-312026-05-0710-Qfiling · viewer · series
18operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$5.9M2025-09-302025-11-1310-Qfiling · viewer · series
19operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.8M2025-06-302026-08-0610-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.

Informational and educational only. Not investment advice. SEC and market data may contain errors.

If you have any comments about this page, the methodology and every line of code that produced it are in the public repository. However, due to the limited number of personnel, we are unable to provide a direct response.

Pages
Home · Companies · Sectors · Calendar · Last night
Screens
Warnings · Price and condition · Then and now · Size bands · Ceased filers
Tools
Time machine · Point in time · Data exports · Run log · Forecast log · EDGAR company search
Method
Method · Coverage · About
Source
GitHub · ezrakruger.cc
Photographs from Wikimedia Commons

bull: Raphael Schön from Vienna, Austria, CC BY 2.0; bear: U. S. Fish and Wildlife Service - Northeast Region, Public domain; elk: Oregon Department of Fish & Wildlife, Public domain; tortoise: NPS, Public domain; sloth: Charles J. Sharp, CC BY-SA 3.0; fox: Cp9asngf, CC BY-SA 4.0; sector-business_equipment: Sangitiana Fararano, CC BY-SA 2.0; sector-healthcare: User:Squidonius, myself, and User:Beliason (assumed)., CC BY-SA 4.0; sector-manufacturing: unknown, CC BY-SA 2.0; sector-shops: Wilfredor, CC BY-SA 4.0; sector-consumer_nondurables: Nielsoncaetanosalmeron, CC BY 4.0; sector-utilities: Lijovklm, CC BY-SA 4.0; sector-consumer_durables: Stilfehler, CC BY-SA 4.0; sector-chemicals: PEO ACWA, CC BY 2.0; sector-energy: Arne Hückelheim, CC BY-SA 3.0; sector-telecom: Wikideas1, CC0; sector-other: Downtowngal, CC BY-SA 4.0.

Updated Oct 9, 2026